Cyto-hematological investigations conducted by our group using the Walderbach platform in various clinical research tasks has leveraged the discovery of circulating cellular markers to indicate bone marrow damage. Imbalances in bone marrow homeostasis seems to cause egress and morphological changes of bone marrow-derived erythroblasts. The clinical discovery denotes a breakthrough in the non-invasive and highly sensitive assessment of bone marrow damage in cancers, diabetes and in principle all systemic diseases. We are now investigating the clinical usefulness of this marker particularly focusing on early stage breast cancer minimal residual disease assessment. The article can be found here.